Phynova Group is a Sino-Western private company focused on the development of botanically based therapeutics for health and personal care. The botanical compounds used in traditional Chinese medicine go through a 'westernised' IP, pre and clinical development process before being commercialised. Two drug candidates are in Phase ll clinical development: Melokinex for post-operative temporary impairment of the gastro-intestinal function especially after abdominal surgery; and PYN17 for the relief of the symptoms of chronic Hep C. Three other compounds are in pre-clinical development: PYN18 (symptoms of dengue fever), PYN22 (obesity and non-fatty liver disease), Phytoback (topical product against MRSA). Consumer and personal care products include: Relivergen (supplement for liver health), InoNorm (blood-glucose control), FatigueFix (relief of fatigue and improvement of sleep) and PhynoRadiance for skin lightening, are at an early development stage.
WHY CHOOSE ED
"Many thanks to @equity_research for a superb Investor Forum. $BMK.L , $VLG.L & $VP.L all interesting companies. I recommend these events. "
"We cannot thank you enough for opening our eyes to private investors."
"MHP believes commissioned research is an important part of the toolkit to attract new investors and improve liquidity. We rate ED's analysts and research very highly as one of the leading providers in this space."
"One of the biggest problems private investors have, is getting access to broker research. It’s basically impossible for many investors. Therefore I feel some commissioned research is really important and a good investment for companies. In my experience ED are far more proactive than other firms in this space."
Blogger and Stockopedia Contributor
"There is a need now, more than ever before, for real insight and clarity to be brought to company messages for investors….I would strongly recommend Equity Development to the management of any company."
Small Cap Equity Salesman
"From early days as a private company through to being established on AIM, I have always been able to rely on ED for wise counsel, perceptive research and introductions to new, supportive shareholders."
"I would like to thank and congratulate you, particularly Liz, on your note. It’s short, sharp, pulls out the key issues and I believe will be a valuable asset for our retail outreach."
"The team at ED consistently produce high quality research and highlight profitable investment opportunities, an invaluable tool for small cap investors in this under researched space."
"I thoroughly enjoyed the investor evening again, and as before its good that you get such an interested audience who engage and ask us all decent questions."